Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
Official title: Optimizing Treatments among People with Cystic Fibrosis in the Era of Highly Effective Modulator Therapy. Short title: Optimizing Treatments among PwCF.
Funded at Rutgers Biomedical and Health Sciences · NIH-11465858 · Data updated 2026-11-12
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | August 15, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $742,459 |
| NIH project number | 1R01HL184443-01A1 |
| Project ID | NIH-11465858 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with cystic fibrosis who are using ETI and may be considering or undergoing adjustment of conventional CF therapies.
✕Less likely to help
Patients not on ETI or not using conventional CF therapies are less likely to benefit from this specific analysis.
What this research studies
If you have CF and are on ETI modulator therapy, this project will look at how keeping or stopping conventional treatments like inhaled dornase alfa or hypertonic saline affects health over time. Researchers will use patient registries and healthcare databases to follow outcomes such as lung function, infections, and adverse effects in diverse care settings. The goal is to provide clearer guidance to clinicians and patients on how to tailor treatment plans in the era of effective modulators. The study will analyze patterns across large groups to identify who might benefit from continuing, modifying, or stopping certain therapies while monitoring safety and quality of life.
Why it matters
Potential benefit: It could help doctors personalize CF treatment plans, potentially reducing treatment burden while maintaining or improving lung health.
How similar studies have gone: Previous real-world studies show varied responses to therapy adjustments, with a need for more comprehensive data in the ETI era.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Setoguchi Iwata, Soko — Rutgers Biomedical and Health Sciences
- Study coordinator: Setoguchi Iwata, Soko
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
-
New peptide medicines to help cystic fibrosis–related diabetes
A small, patient-friendly study tests new peptide-based therapies aimed at improving insulin production and reducing pancreatic inflammation in people with CFRD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.